Bicifadine is DOV Pharmaceutical Inc.’s novel analgesic. Yesterday (11th April) the company announced that the US Patent and Trademark Office has issued a Notice of Allowance for its patent application on a new polymorphic (or crystalline) form of bicifadine.
"We believe this patent will further increase bicifadine's significant commercial potential and marks an important milestone in the compound's development," said Dr. Leslie Hudson, CEO and President of DOV. "DOV has additional formulation, process and novel use patent filings pending for bicifadine and we are committed to further enhancing the intellectual property portfolio to protect the market for this important new analgesic."
Currently, bicifadine is under trial in three Phase III clinical trials in chronic low back pain patients and in two Phase II clinical trials: one in patients with neuropathic pain and one in patients with osteoarthritis of the hip or knee. In the first half of 2007, DOV Pharma Inc. intends to file a New Drug Application (NDA) for bicifadine.
Source: PR Newswire
.jpg)
Comment Preview